ArticleUnited European gastroenterology journal2018
Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis.
Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulations.JHEP reports : innovation in hepatology · 2026Article
- Beyond futility: The history and potential of liver transplantation in cholangiocarcinoma.World journal of transplantation · 2025Review
- Predictors of survival in autoimmune liver disease overlap syndromes.World journal of hepatology · 2024Article
- TheEClinicalMedicine · 2024Article
- Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review.eGastroenterology · 2024Review
- Sex differences in chronic liver disease and benign liver lesions.JHEP reports : innovation in hepatology · 2023Review
- Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.Cancers · 2023Review
- Novel histological scoring for predicting disease outcome in primary sclerosing cholangitis.Histopathology · 2022Article
- Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice.Journal of personalized medicine · 2022Review
- Gut Microbiome of Children and Adolescents With Primary Sclerosing Cholangitis in Association With Ulcerative Colitis.Frontiers in immunology · 2020Article
- Association between serum IgG level and clinical course in primary sclerosing cholangitis.BMC gastroenterology · 2019Article
- Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma.Journal of liver · 2018Article
- Diagnosis of Primary Sclerosing Cholangitis Beyond Childhood is Associated with Worse Outcomes.Journal of clinical and experimental hepatologyArticle
- Racial Disparities in Comorbidity Patterns of Early-Onset Liver Cancer: A Machine Learning Analysis.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe median age of diagnosis of primary sclerosing cholangitis (PSC) is ∼30-40 years.
objectiveWe aimed to analyse disease progression and liver-dependent survival in patients diagnosed with PSC after 50 years of age.
methodsPatients with PSC were analysed with regard to their age at diagnosis. Patients with a first diagnosis of PSC after the age of 50 years were considered as the late-onset group.
resultsA total of 32/215 (14.9%) patients were diagnosed with PSC after 50 years of age. The proportion of females was significantly higher among patients with late-onset PSC (48.4 vs. 27.3%;
conclusionsPatients with later age at diagnosis of PSC displayed a different clinical phenotype with a different sex ratio, immune status and an increased risk for progressive liver failure and biliary malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.